Madison Vaccines closes on financing round

A Madison company that is developing a prostate cancer vaccine closed on an $8 million financing round led by Venture Investors. Madison Vaccines, Inc., is working on two vaccines, including one that is currently in Phase 2 clinical trials, according to a report in the Wisconsin State Journal. Other investors include WARF, Venture Management, and the State of Wisconsin Investment Board.